VSV-IFNβ-NIS
Gene therapyexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2018 (NCT03647163)
Timeline
Indications
Mechanism of action
- Oncolytic virusOTHER
Oncolytic virus other
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04291105 | Phase 2 | Mar 31, 2020 | Regeneron, Union Therapeutics, Vyriad, Inc. |
| NCT03647163 | Phase 1 | Nov 1, 2018 | Mayo Clinic, Vyriad, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vyriad, Inc. | For profit | 2 | 2 | 2 | 2018 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Regeneron | For profit | 1 | 0 | 1 | 2020 |
| Union Therapeutics | For profit | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1